Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Anas, Gazzah"'
Autor:
Damien Vasseur, Ludovic Bigot, Kristi Beshiri, Juan Flórez-Arango, Francesco Facchinetti, Antoine Hollebecque, Lambros Tselikas, Mihaela Aldea, Felix Blanc-Durand, Anas Gazzah, David Planchard, Ludovic Lacroix, Noémie Pata-Merci, Catline Nobre, Alice Da Silva, Claudio Nicotra, Maud Ngo-Camus, Floriane Braye, Sergey I. Nikolaev, Stefan Michiels, Gérôme Jules-Clement, Ken André Olaussen, Fabrice André, Jean-Yves Scoazec, Fabrice Barlesi, Santiago Ponce, Jean-Charles Soria, Benjamin Besse, Yohann Loriot, Luc Friboulet
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-16 (2024)
Abstract Background Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments throu
Externí odkaz:
https://doaj.org/article/e6a5668f34d34175ab097af1e5bb22e4
Autor:
Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-14 (2022)
Abstract Background We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NC
Externí odkaz:
https://doaj.org/article/cc022ab82e6e4fd69d684a17c4dfa3ff
Autor:
John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 277-287 (2021)
Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigali
Externí odkaz:
https://doaj.org/article/2e9537a22ea94fefa65b2b3c6cd4e048
Autor:
Emily Alouani, Anas Gazzah, Sandrine Mercier, Ratislav Bahleda, Antoine Hollebecque, Jean-Marie Michot, Capucine Baldini, Samy Ammari, Stephane Champiat, Aurelien Marabelle, Sophie Postel-Vinay, Vincent Ribrag, Yohann Loriot, Santiago Ponce Aix, Linda Mahjoubi
Publikováno v:
European Journal of Cancer. 188:1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64a7c81162b4ec55e98b55099563639d
https://doi.org/10.1016/j.ejca.2023.04.006
https://doi.org/10.1016/j.ejca.2023.04.006
Autor:
Damien Vasseur, Hela Sassi, Arnaud Bayle, Marco Tagliamento, Benjamin Besse, Christophe Marzac, Ahmadreza Arbab, Nathalie Auger, Sophie Cotteret, Mihaela Aldea, Félix Blanc-Durand, Arthur Géraud, Anas Gazzah, Yohann Loriot, Antoine Hollebecque, Patricia Martín-Romano, Maud Ngo-Camus, Claudio Nicotra, Santiago Ponce, Madona Sakkal, Olivier Caron, Cristina Smolenschi, Jean-Baptiste Micol, Antoine Italiano, Etienne Rouleau, Ludovic Lacroix
Publikováno v:
Cells, Vol 11, Iss 12, p 1901 (2022)
FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It g
Externí odkaz:
https://doaj.org/article/2e99673fed1041c0a965376c66400eb2
Autor:
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, Giacomo Massa, Giulio Metro, Isabelle Monnet, Patricia Gomez Iranzo, Fabrizio Tabbo, Emilio Bria, Florian Guisier, Damien Vasseur, Colin R. Lindsay, Santiago Ponce-Aix, Sophie Cousin, Fabrizio Citarella, Vincent Fallet, Jose Nicolas Minatta, Anna Eisert, Hortense de Saint Basile, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Jordi Remon Masip, Judith Raimbourg, Safae Terrisse, Alessandro Russo, Diego Cortinovis, Philippe Rochigneux, David James Pinato, Alessio Cortellini, Camille Leonce, Anas Gazzah, Maria-Rosa Ghigna, Roberto Ferrara, Filippo Gustavo Dall’Olio, Francesco Passiglia, Vienna Ludovini, Fabrice Barlesi, Enriqueta Felip, David Planchard, Benjamin Besse
Publikováno v:
Scientia
Chemotherapy; Non–small cell lung cancer; RET inhibitors Quimioteràpia; Càncer de pulmó de cèl·lules no petites; Inhibidors de RET Quimioterapia; Cáncer de pulmón de células no pequeñas; Inhibidores de RET Introduction Nearly 1% to 2% of N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57f7bd4756ed222514ab170ab21d1c3d
https://doi.org/10.1016/j.jtho.2022.12.018
https://doi.org/10.1016/j.jtho.2022.12.018
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4ebaa45d1da62d0ac5f9e5a60659de
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
Autor:
Lauren Seknazi, Arthur Geraud, Vincent Goldschmidt, Capucine Baldini, Stéphane Champiat, Christophe Massard, Sophie Postel-Vinay, Aurelien Marabelle, Rastilav Bahleda, Antoine Hollebecque, Cristina Smolenschi, Anas Gazzah, Jean-Marie Michot, Patricia Martin-Romano, Aurore Vozy, Perrine Vuagnat, François-Xavier Danlos, Arnaud Bayle, Linda Mahjoubi, Barbara Pistilli, Yohann Loriot, Santiago Ponce-Aix, Kaissa Ouali
Publikováno v:
Cancer Research. 83:P2-13
Background: Breast cancer (BC) is the most frequent cancer and the second leading cause of cancer death for women. Although there is a need of new treatments to improve BC outcome, patients with BC are still under-represented in early phase trials, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf3c7ec9e4e98d11575b6815653da494
https://doi.org/10.1158/1538-7445.sabcs22-p2-13-02
https://doi.org/10.1158/1538-7445.sabcs22-p2-13-02
Autor:
Emiliano Calvo, Alexander Spira, María de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, Philippe A. Cassier, Kiyotaka Yoh, Antoine Italiano, Victor Moreno, Katriina Peltola, Takashi Seto, Ryo Toyozawa, Daniel E. Afar, Stefan Englert, Philip Komarnitsky, Stacie Lambert, Apurvasena Parikh, Gregory Vosganian, Bo Gao
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100405- (2021)
Background: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced
Externí odkaz:
https://doaj.org/article/e1966145ff134f7d8b7360173186cc8e
Autor:
François-Xavier Danlos, Matthieu Texier, Bastien Job, Severine Mouraud, Lydie Cassard, Capucine Baldini, Andrea Varga, Andrey A. Yurchenko, Audrey Rabeau, Stéphane Champiat, Diane Letourneur, Delphine Bredel, Sandrine Susini, Yuna Blum, Aurelien Parpaleix, Cedric Parlavecchio, Lambros Tselikas, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Mathieu Rouanne, Saloomeh Rafie, Alae Abbassi, Ines Kasraoui, Marie Breckler, Siham Farhane, Samy Ammari, Salim Laghouati, Anas Gazzah, Ludovic Lacroix, Benjamin Besse, Nathalie Droin, Marc Deloger, Sophie Cotteret, Julien Adam, Laurence Zitvogel, Sergey I. Nikolaev, Nathalie Chaput, Christophe Massard, Jean-Charles Soria, Carlos Gomez-Roca, Gerard Zalcman, David Planchard, Aurelien Marabelle
Publikováno v:
Cancer Discovery
Cancer Discovery, 2023, pp.OF1-OF22. ⟨10.1158/2159-8290.CD-22-0886⟩
Cancer Discovery, 2023, pp.OF1-OF22. ⟨10.1158/2159-8290.CD-22-0886⟩
Cancer immunotherapy combinations have recently been shown to improve the overall survival of advanced mesotheliomas, especially for patients responding to those treatments. We aimed to characterize the biological correlates of malignant pleural meso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5017878bdc841681bdf4cd403e9f0c10
https://doi.org/10.1158/2159-8290.cd-22-0886
https://doi.org/10.1158/2159-8290.cd-22-0886